Skip to main content
VRTX logo

Vertex Pharmaceuticals Incorporated (VRTX) Stock: Price, Forecast & Analyst Target

Vertex Pharmaceuticals Incorporated (VRTX) — MoonshotScore 90/100 (Exceptional band), calculated Nov 18, 2026. Price $536.45 (+0.42%), as of the Nov 18, 2026 trading session; market cap $136B. Expected results Feb 11, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$536.45 +$2.25 (+0.42%) Market Cap $136B

Vertex Pharmaceuticals Incorporated · VRTX · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-12: Vertex is a commercial rare-disease drugmaker whose profits still come overwhelmingly from cystic fibrosis treatments, especially Trikafta and Kaftrio. The case rests on whether medicines such as Alyftrek and Casgevy can broaden that earnings base while preserving the unusually strong economics of the cystic fibrosis franchise.

Price as of Nov 18, 2026

Key Statistics

90 of 100

MoonshotScore v2 · Vertex Pharmaceuticals (VRTX)

Exceptional
Business Quality Elite (93)
Financial Safety Sound (74)
Valuation Rich (39)
Growth Durability Compounding (84)
Momentum Surging (85)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and durable growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 11, 2027
  • Altman Z 8.68 · Piotroski F 4

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for VRTX (57 recorded, newest six shown)
RecordedScoreBand
94Exceptional
94Exceptional
94Exceptional
94Exceptional
90Exceptional
90Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$536.45
Change on the day+0.42%
52-week range$412.27–$568.67
Market capitalisation$136B—
Price / earnings (trailing)34.11
Shares traded on the day1.29M
Beta (volatility vs the S&P 500)0.32

Why Vertex Pharmaceuticals scores 90

Dr. Mira Sol, the Stock Expert AI TV data character
Business Quality carries the score; Valuation is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
90Exceptional
  • Business Quality93
  • Financial Safety74
  • Valuation39
  • Growth Durability84
  • Momentum85

Share price, last 12 months +30.8%

$421.20 $550.87

What the price assumes

17.7% a year of free-cash-flow growth for ten years is what a $139.62B market value ( snapshot) asks for.

  • Price implies, next ten years17.7%
  • Free cash flow, last 5 years1.3%
  • Revenue, last 5 years14.2%
  • Analysts' revenue path, 2026–203011.9%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $3.20B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 6 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 4.6% either way.

  1. -2.0%Feb ’24
  2. +2.3%May ’24
  3. -0.3%Aug ’24
  4. +6.1%Nov ’24
  5. -3.0%Feb ’25
  6. -10.2%May ’25
  7. -18.9%Aug ’25
  8. -0.9%Nov ’25
  9. +6.6%Feb ’26
  10. +0.1%May ’26
  11. +0.3%Aug ’26
  12. -5.0%Nov ’26
Next-session move EPS beat (6) EPS in line (2) EPS miss (4)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
MissIn line-5.0%-1.4%
In lineBeat+0.3%+9.8%
BeatIn line+0.1%+2.7%
MissIn line+6.6%+3.4%
BeatIn line-0.9%-1.0%
BeatBeat-18.9%-19.0%
MissMiss-10.2%-12.3%
In lineBeat-3.0%-1.5%
BeatBeat+6.1%+6.5%
MissMiss-0.3%-6.0%
BeatBeat+2.3%+7.2%
BeatIn line-2.0%-1.4%

Misses cost real money here: the average first-session move after a miss was -2.2%.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “phase study”, “pivotal development”, “rare endocrinology” — none of them came up in Q2 FY2026.
  • Gone quiet: “acute pain”, “endocrine diseases”, “iii study”, “prescription growth” — regular themes last call, absent this time.

The tone held steady from one call to the next; what changed is the subject matter, not the confidence.

Our track record on this stock

Since the score went from 98 to 90 while the share price moved -2.0% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 86% of 56 rate it a buy; the average target sits +8.2% from the price of $536.45.
  • Last 90 days: 13 rating actions, every one a reaffirmation.
  • Our signals: Exceptional band; strongest pillar Business Quality (93), weakest Valuation (39).

Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $409, high $559, latest $536. 4 reported quarters marked, 1 above and 3 below the recorded estimate. $559 $409 high $559 Feb 12, 2026 · Earnings results · reported below the recorded estimate · close $4911May 4, 2026 · Earnings results · reported above the recorded estimate · close $4242Aug 3, 2026 · Earnings results · reported below the recorded estimate · close $4773Nov 2, 2026 · Earnings results · reported below the recorded estimate · close $5594 Oct 17, 2025 Nov 18, 2026 · $536 $417Oct 17, 2025$426Oct 31, 2025$437Nov 14, 2025$434Nov 28, 2025$452Dec 12, 2025$463Dec 26, 2025$464Jan 9, 2026$468Jan 23, 2026$478Feb 6, 2026$477Feb 20, 2026$457Mar 6, 2026$454Mar 20, 2026$439Apr 2, 2026$441Apr 17, 2026$424May 1, 2026$437May 15, 2026$448May 29, 2026$445Jun 12, 2026$491Jun 26, 2026$485Jul 10, 2026$477Jul 24, 2026$496Aug 7, 2026$548Aug 21, 2026$546Sep 4, 2026$508Sep 18, 2026$505Oct 2, 2026$500Oct 16, 2026$559Oct 30, 2026$539Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Vertex Pharmaceuticals (VRTX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Weak
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Neutral
Debt/Equity Neutral
ROE Strong
Gross Margin Moderate

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Vertex Pharmaceuticals (VRTX), and what does it report?

Short answer · as of

Vertex discovers, develops and markets therapies aimed at specific disease mechanisms, then reaches patients through specialty pharmacies, distributors, hospitals and clinics.

Its reported revenue measures commercial product sales rather than the scientific breadth of its pipeline, and Trikafta and Kaftrio remain the dominant product line by a wide margin.

This is not a development-stage biotechnology company funded mainly by outside capital. An established cystic fibrosis franchise produces substantial profit and operating cash flow, which in turn finances research across pain, blood disorders, kidney disease, diabetes and other serious conditions.

2 · Latest results

What do the latest results show for Vertex Pharmaceuticals (VRTX)?

The latest quarter brought a sharp sequential revenue rebound to the highest level in the reported series. Gross profit, operating income, net income and diluted earnings also increased, while research spending edged higher and selling and administrative expense rose more noticeably. Revenue exceeded the market estimate, although adjusted earnings landed just below it.

Management expects Casgevy and other newer products to carry higher production costs than the small-molecule cystic fibrosis portfolio. That mix shift does not explain the latest revenue increase, but it does explain why expanding beyond cystic fibrosis may add sales without matching the legacy franchise’s gross margin.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$3.44B Nov 2, 2026
Latest report · revenue estimate
$3.42B Nov 2, 2026
Latest report · revenue vs estimate
Above estimate Nov 2, 2026
Latest report · EPS vs estimate
Below estimate Nov 2, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 2, 2026$3.44B$3.42B$4.7600$4.8200
Aug 3, 2026$3.33B$3.23B$4.7300$4.7400
May 4, 2026$2.99B$2.99B$4.4700$4.2400
Feb 12, 2026$3.19B$3.18B$5.0300$5.1100
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$3.08B$1.08B$4.20 (diluted)
Q4 FY2025$3.19B$1.19B$4.65 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Vertex Pharmaceuticals (VRTX)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Vertex combines high gross and operating margins with positive operating cash flow across every quarter shown. Cash and investments stand far above total debt, and the short-term liquidity balance has climbed through the latest reporting periods, leaving ample capacity for research, commercialization and strategic transactions.

The financial vulnerability is product concentration rather than funding pressure. If cystic fibrosis growth weakens before newer medicines become material, heavy research and commercial spending would bear on a narrower growth engine; rising Casgevy contribution could also dilute gross margin because its production economics are less favorable. The valuation already reflects substantial profitability, so weaker execution would matter even without balance-sheet stress.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 34.11 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Vertex Pharmaceuticals (VRTX)?

Short answer · as of

The next earnings report is expected on Feb 11, 2027. The number it tests is the $18.16 EPS analysts carry for it.

Watch whether overall product revenue keeps advancing as Alyftrek expands and Casgevy contributes more, rather than treating pipeline breadth as proof of commercial diversification. The next earnings release should also be tested against management’s expectation for gross margin near its recent level and operating expense near the upper end of guidance.

Cash conversion deserves equal attention: operating cash flow has remained strong but variable from period to period. Updated guidance around the announced transaction’s closing, along with the next periodic filing, should clarify whether the deal changes near-term revenue or expense expectations beyond the modest impact management currently anticipates.

5 · Peer comparison

How does Vertex Pharmaceuticals compare with its peers?

Short answer

Vertex Pharmaceuticals's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Vertex differs from many biotechnology peers because approved rare-disease medicines already support strong margins, durable cash generation and a net cash position large enough to fund an ambitious pipeline internally. It is therefore better understood as a profitable cystic fibrosis incumbent pursuing therapeutic expansion than as a collection of clinical-stage projects.

That maturity comes with an unusual concentration tradeoff. Trikafta and Kaftrio dominate revenue, while diversification through products such as Alyftrek and Casgevy introduces different commercial and manufacturing economics. Comparable drug developers may offer broader revenue mixes or greater pipeline dependence; Vertex couples financial resilience with a particularly concentrated commercial foundation.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$942.04 Nov 19, 2026$59.2B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Vertex Pharmaceuticals (VRTX) — this page$536.45$136B90
Sanofi (SNY) Named competitor$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
Novo Nordisk A/S (NVO) Same industry, near in market value$39.43 Nov 18, 2026$174B87 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$59.56 Nov 18, 2026$122B85 5-pillar Nov 18, 2026
CVS Health Corporation (CVS) Named competitor$80.06 Nov 19, 2026$102B81 5-pillar Nov 18, 2026
Medtronic plc (MDT) Named competitor$100.72 Nov 18, 2026$129B81 5-pillar Nov 18, 2026
GSK plc (GSK) Named competitor$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$350.00 – $665.00
Consensus target
$579.29
Median target
$608.00
Revenue estimate
$13.26B
EPS estimate
$18.16

Consensus record · Captured .

Measured against a quoted price of $536.45 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
20
Identified insiders
12
Purchases
0
Sales
10
Other transactions
10

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held VRTX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.08%$18.25MAdded +221.4% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Vertex Pharmaceuticals (VRTX)?

Read these with our analysis →

Common Questions About VRTX (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Why do Trikafta and Kaftrio matter so much to Vertex?

They account for the great majority of reported product revenue, making cystic fibrosis demand the main driver of current business performance. Alyftrek and other products are broadening the portfolio, but they have not displaced that dependence.

How could Casgevy change Vertex’s margin profile?

Casgevy carries higher production costs than Vertex’s small-molecule cystic fibrosis drugs. Greater contribution would diversify revenue while putting downward pressure on the blended gross margin unless offset elsewhere.

What role does Alyftrek play beside Trikafta and Kaftrio?

Alyftrek is reported as a distinct and meaningful product line, but it remains far smaller than Trikafta and Kaftrio. Its progress matters because it can extend Vertex’s cystic fibrosis franchise even as the company pursues diversification beyond that disease.

Can Vertex fund Casgevy and its broader pipeline without new borrowing?

Current finances provide substantial internal capacity: operating cash flow has stayed positive, while cash and investments comfortably exceed debt. Research spending remains heavy, but the balance sheet does not presently make borrowing the necessary source of pipeline funding.

What is the VRTX stock price today?

The last price recorded for Vertex Pharmaceuticals Incorporated (VRTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the VRTX price target?

The analyst consensus price target for Vertex Pharmaceuticals Incorporated (VRTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.

Sources: the source register lists the 44 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 5 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • 1. What is Vertex Pharmaceuticals (VRTX), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • 2. What do the latest results show for Vertex Pharmaceuticals (VRTX)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Vertex Pharmaceuticals (VRTX)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Revenue by segment; Management outlook — dated call excerpts
  • 4. What should you watch next at Vertex Pharmaceuticals (VRTX)?: Revenue by segment; Next earnings report; Analyst revenue and earnings estimates (average); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts; Recent SEC filings; Most recent periodic reports
  • 5. How does Vertex Pharmaceuticals compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value; Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • FAQ: Why do Trikafta and Kaftrio matter so much to Vertex?: Business description; Revenue by segment
  • FAQ: How could Casgevy change Vertex’s margin profile?: Management outlook — dated call excerpts; Trailing twelve-month ratio set; Revenue by segment
  • FAQ: What role does Alyftrek play beside Trikafta and Kaftrio?: Revenue by segment; Business description
  • FAQ: Can Vertex fund Casgevy and its broader pipeline without new borrowing?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold VRTX

Funds in our ETF coverage that list VRTX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Evolved U.S. Innovative Healthcare ETF (IEIH)5.13%
Natixis Loomis Sayles Focused Growth ETF (LSGR)4.85%
Global X - Genomics & Biotechnology ETF (GNOM)4.32%
ClearBridge All Cap Growth ESG ETF (CACG)3.10%
PRMR ETF2.09%
One Global ETF (FFND)1.74%